Prenatal Vitamin
Phase 3Small molecule
Prenatal Vitamin is one of 13 small molecule programs targeting Vitamin D Deficiency. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Vitamin D Deficiency
#DrugCompanyPhaseTrials
1Calciferol
Alnylam PharmaceuticalsApproved
Rayaldee
OOrganon and Co
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Tums
OtsukaPhase 3
Femara
NovartisPhase 2
Alendronate Sodium
Mylan Pharmaceuticals IncPhase 3
Calcium Gluconate
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Phase 2
Prenatal Vitamin
CChildren's Hospital Medical Center, Cincinnati
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Vitamin D Deficiency1 trial
Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants
Completed·—·Phase 3·NCT00610688·192 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prenatal Vitamin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details